ConductScience.org, home

Comparison · NCT01700192-3c9565ef

MK-8237 vs Placebo: Number of Participants Who Experience At Least One Adverse Event (AE)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. MK-8237 vs Placebo: Number of Participants Who Experience At Least One Adverse Event (AE). Trial comparisons, record NCT01700192-3c9565ef. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01700192-3c9565ef

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.910.8870.928wilson
Risk in group 20.730.6970.761wilson
Risk difference, group 1 minus group 20.1790.1410.217newcombe hybrid score
Risk ratio, group 1 over group 21.251.191.31log
Odds ratio, group 1 over group 23.732.765.02log
Number needed to treat, for one more participant with the outcome on MK-8237 than on Placebo5.574.67.08from the risk difference interval

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1MK-8237Participants took MK-8237 12 DU rapidly dissolving tablets administered sublingually q.d. for up to one year.676743OG000
Group 2PlaceboParticipants took placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d. for up to one year.539738OG001

Outcome

Type
PRIMARY
Title
Number of Participants Who Experience At Least One Adverse Event (AE)
Description
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
Time frame
Up to 54 weeks
Population
The All Participants as Treated (APaT) population consists of all randomized participants who received at least 1 dose of study drug (data presented according to actual treatment received).

Source ClinicalTrials.gov

Trial

Title
Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
NCT number
NCT01700192
Phases
PHASE3
Conditions
Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal
Interventions
MK-8237 tablets, Placebo tablets, Rescue Medication: Self-Injectable Epinephrine, Rescue Medication: Loratadine tablets, Rescue Medication: Olopatadine ophthalmic drops, Rescue Medication: Mometasone furoate nasal spray
Lead sponsor
ALK-Abelló A/S
Results first posted
2017-03-03

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01700192-3c9565ef